ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
AIT-082 Phase 1B Study

This study has been completed.

Sponsored by: National Institute on Aging (NIA)
Information provided by: National Institute on Aging (NIA)
ClinicalTrials.gov Identifier: NCT00000180
  Purpose

AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits.

This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.


Condition Intervention Phase
Memory Disorders
Drug: AIT-082
Phase I

MedlinePlus related topics:   Memory   

ChemIDplus related topics:   Nerve growth factor    Ait 082   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control
  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000180

Locations
United States, California
University of California, San Diego    
      San Diego, California, United States, 92093-0949
United States, Indiana
Indiana University Alzheimer's Center    
      Indianapolis, Indiana, United States, 46202
United States, Michigan
University of Michigan    
      Ann Arbor, Michigan, United States, 48109-0322
United States, Missouri
Washington University    
      St. Louis, Missouri, United States, 63110

Sponsors and Collaborators

Investigators
Principal Investigator:     Michael Grundman, M.D., M.P.H.     University of California, San Diego    
  More Information

Publications of Results:

Study ID Numbers:   IA0008, 3U01AG10483-08S2
First Received:   October 29, 1999
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00000180
Health Authority:   United States: Federal Government

Keywords provided by National Institute on Aging (NIA):
Memory  
Mild cognitive impairment  
Nerve growth factors  

Study placed in the following topic categories:
Signs and Symptoms
Neurologic Manifestations
Neurobehavioral Manifestations
Memory Disorders

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on August 21, 2008




Links to all studies - primarily for crawlers